Abstract
The single-chain antibody (scFv) made by recombinant DNA technology is one of the most useful tools for basic research and clinical applications. To develop a novel targeted gene delivery method, we engineered the scFv gene for the antibody against human epidermal growth factor (EGF) receptor by connecting with DNA sequences for various oligopeptides with negative or positive charges. The resulting recombinant genes encoding artificial scFv with negative or positive tails were expressed in Escherichia coli and yeast Pichia pastris. In E. coli, all the scFv with negatively charged tails were expressed but mainly as an insoluble form, whereas those with positively charged tails were barely expressed. In yeast P. pastris, all the scFv with negatively charged tails were efficiently expressed and secreted into the culture medium. Addition of high salt into the yeast culture increased their secretion. Purification procedure was established for the scFv with the longest negatively charged tail (D4S × 5), yielding 5 mg/l with a purity of over 95%. The scFv-D4S × 5 was designated as a recombinant immunoporter, which was then mixed with plasmid DNA and polyethylenimine (PEI). The resulting DNA/PEI/immunoporter complex (designated recombinant immunogene) exhibited efficient gene delivery to EGF receptor overexpressing A431 tumor cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kaneko S et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55: 5283–5287.
Ido A et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995; 55: 3105–3109.
Romanczuk H et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther 1999; 10: 2615–2626.
Smith JS et al. Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc Natl Acad Sci USA 1999; 96: 8855–8860.
Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL . A retroviral vector system ‘STITCH’ in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther 1998; 5: 1195–1203.
Jiang A et al. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol 1998; 72: 10148–10156.
Martin F A et al. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope. Hum Gene Ther 1998; 9: 737–746.
Chen J, Gamou S, Takayanagi A, Shimizu N . A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett 1994; 338:167–169.
Shimizu N, Chen J, Gamou S, Takayanagi A . Immunogene approach toward cancer therapy using epidermal growth factor receptor-mediated gene delivery. Cancer Gene Ther 1996; 3: 113–120.
Chen J et al. Receptor-mediated gene delivery using the Fab fragments of anti-epidermal growth factor receptor antibodies: improved immunogene approach. Cancer Gene Ther 1998; 5: 357–364.
Ohtake Y et al. Ex vivo delivery of suicide genes into melanoma cells using epidermal growth factor receptor-specific Fab immunogene. Jpn J Cancer Res 1999; 90:460–468.
Chen J et al. Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinomas using anti-epidermal growth factor receptor antibody: immunogene approach. Hum Gene Ther 1998; 9: 2673–2681.
Hochman J, Inbar D, Givol D . An active antibody fragment (Fv) composed of the variable portions of heavy and light chains. Biochemistry 1973; 12: 1130–1135.
Ward ES et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989; 341: 544–546.
Field H, Yarranton GT, Rees AR . Expression of mouse immunoglobulin light and heavy chain variable regions in Escherichia coli and reconstitution of antigen-binding activity. Protein Eng 1990; 3: 641–647.
Glockshuber R, Stadlmuller J, Pluckthun A . Mapping and modification of an antibody hapten binding site: a site-directed mutagenesis study of McPC603. Biochemistry 1991; 30: 3049–3054.
McManus S, Riechmann L . Use of 2D NMR, protein engineering, and molecular modeling to study the hapten-binding site of an antibody Fv fragment against 2-phenyloxazolone. Biochemistry 1991; 30: 5851–5857.
Takahashi H, Igarashi T, Shimada I, Arata Y . Preparation of the Fv fragment from a short-chain mouse IgG2a anti-dansyl monoclonal antibody and use of selectively deuterated Fv analogues for two-dimensional 1H NMR analyses of the antigen-antibody interactions. Biochemistry 1991; 30: 2840–2847.
Boussif O et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297–7301.
Acknowledgements
This work was supported by a Fund for ‘Research for the Future’ Program from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Suzuki, M., Takayanagi, A. & Shimizu, N. Recombinant single-chain antibodies with various oligopeptide tails for targeted gene delivery. Gene Ther 10, 781–788 (2003). https://doi.org/10.1038/sj.gt.3301952
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301952